Daré Bioscience, Inc.
DARE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $3 | $10 | $0 |
| % Growth | -99.7% | -71.9% | – | – |
| Cost of Goods Sold | $14 | $22 | $30 | $0 |
| Gross Profit | -$14 | -$19 | -$20 | -$0 |
| % Margin | -146,110.2% | -670.6% | -201.4% | – |
| R&D Expenses | $14 | $22 | $30 | $31 |
| G&A Expenses | $8 | $11 | $11 | $8 |
| SG&A Expenses | $9 | $12 | $11 | $8 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | -$14 | -$21 | -$30 | $0 |
| Operating Expenses | $9 | $12 | $11 | $39 |
| Operating Income | -$23 | -$31 | -$31 | -$39 |
| % Margin | -239,692.2% | -1,101.9% | -313.9% | – |
| Other Income/Exp. Net | $19 | $1 | $0 | $0 |
| Pre-Tax Income | -$4 | -$30 | -$31 | -$39 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$30 | -$31 | -$39 |
| % Margin | -41,430.9% | -1,074.2% | -309.5% | – |
| EPS | -0.48 | -4.15 | -4.39 | -7.52 |
| % Growth | 88.4% | 5.5% | 41.6% | – |
| EPS Diluted | -0.48 | -4.15 | -4.39 | -7.52 |
| Weighted Avg Shares Out | 8 | 7 | 7 | 5 |
| Weighted Avg Shares Out Dil | 8 | 7 | 7 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$23 | -$31 | -$31 | -$39 |
| % Margin | -239,259.6% | -1,093.4% | -313.6% | – |